Sydney M Crago

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration (iAMD) and diabetic retinal eye disease.

Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

This trial is designed to evaluate 4D-150 in diabetic macular edema.

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding you may have missed.

ArMaDa clinical trial is set to assess the safety and efficacy of unilateral subretinal administration of OCU410 in patients with GA

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The report details the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug Administration (FDA).

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.